In today's Biz Pulse, gain insight into how:

• Better-informed patients (not retail-style consumers) and shared decision-making time with clinicians can drive smarter, value-based care.

• Healthcare leaders can stress-test AI vendors before signing by asking about training data fit, ongoing validation, accountability, and exit plans.

• Cell and gene therapies are outpacing system readiness, making cost, patient identification, and scalable clinical expertise (including rural access) the next big hurdles.

Each of these articles is penned by members of Forbes Business Council, successful business owners shaping the future of business.

Let’s dive in!

Patients Aren’t Shoppers: Build Informed Care Partners

Healthcare often asks people to make high-stakes choices with less clarity than they use for everyday purchases. The real fix is not turning patients into “better consumers,” but helping them become better-informed partners who can weigh options with context, confidence, and clinician support.

Here are the top takeaways:

🧭 Transparency Needs Interpretation: Prices and ratings rarely explain diagnoses, necessity of tests, or real tradeoffs across risk, quality of life, and cost.

🤝 Trust Should Enable Questions: Strong care decisions come from shared decision-making, not blind acceptance.

⏱️ Time Is the Missing Ingredient: Documentation and reimbursement pressures squeeze the conversations patients need most.

🧪 More Care Is Not Always Better: Extra tests and procedures can raise costs and complications without improving outcomes.

📊 Measure Outcomes, Not Activity: Systems still track volume more consistently than safety and results, limiting accountability.

🧠 Tech Can Prepare Patients: AI and digital tools can explain terminology, summarize options, and surface smarter questions before visits.

Read The Full Article >

Before You Buy Clinical AI: Top Questions That Save You Later

Healthcare AI is already in daily use, but many teams still buy it like standard enterprise software. The smarter approach is diligence that tests safety, staying power, and accountability well past go-live.

Start with these vendor questions:

🧬 Training Data Fit: What population trained the model, and how does it compare to your patients and setting?

🧾 Local Validation Plan: What will be validated on-site, by whom, and how often will performance be rechecked (including HTI-1 attributes)?

📉 Model Drift Response: How is degradation monitored, what triggers action, and can the tool be retrained or pulled fast (in the contract)?

🌪️ Bad-day Workflow: Show ambiguous cases, incomplete records, and false positives. Can clinicians understand and override outputs, with overrides captured?

⚖️ Accountability Clarity: Who owns risk when outputs are wrong, including indemnification and what counts as a defect?

🎓 Training & Support: What education is included for current roles and new hires later, given the limited AI training physicians report?

Read The Full Article >

Cell & Gene Therapy Is Here But Is The System Ready?

Cell and gene therapies are shifting care from ongoing symptom control to one-time, potentially durable interventions. The science is moving fast, but access hinges on whether health systems, payers, and providers can modernize how they identify patients, pay for treatment, and deliver highly specialized care, especially beyond major academic centers.

Key hurdles healthcare leaders should tackle:

💸 Upfront Cost vs Long-term Value: A hemophilia B gene therapy can cost $3.5M, yet years of ongoing care may add up to more.

🧾 Unpredictable Reimbursement: Single-case agreements can delay payment by well over 100 days, compared with a typical 45-day turnaround.

🧍 Eligible Patients Are Missed: Only an estimated 20% of eligible patients receive these therapies today.

🛰️ Rural Access Gaps: Travel, coordination, and stronger rural-urban provider communication remain major barriers.

🧠 Expertise Must Scale: With 4,000+ therapies in development, community settings need training, protocols, and long-term tracking.

🔄 Collaboration Is the Unlock: Better data-sharing and coordinated financing can help move these therapies from niche to scalable care.

Read The Full Article >

Wrapping Up

If these articles sparked your interest, we have a network that you will love: Forbes Business Council.

This exclusive, vetted community brings together seasoned business leaders — founders, CEOs, partners, and other senior-level leaders of successful companies.

Put yourself at the forefront of innovation with access to publishing opportunities on Forbes.com, a personalized, SEO-friendly Executive Profile, and the chance to network with other respected leaders in the field.

Join Forbes Business Council today, and become part of a group driving meaningful innovation in business.